Selected Posters and Abstracts
Enfuvirtide (Fuzeon)
•[P45] Treatment of antiretroviral experienced, enfuvirtide naive, advanced HIV patients with a boosted tipranavir / enfuvirtide based regimen in clinical practice: 24-week results of an Italian cohort
G Parruti and others.
•[P184] Prospective study assessing injection site reactions, quality of life and enfuvirtide administration preference using Biojector versus needles
M Loutfy and others.
•[P79] Evaluation of the local tolerance and quality of life in 60 HIV-1 infected patients treated with an ARV regimen containing enfuvirtide: SURCOUF cohort
C Allavena and others.
•[P205] Lack of virologic response to the combination of tipranavir/ritonavir + enfuvirtide in treatment experienced HIV-infected persons with multi-drug resistant virus can be predicted by the presence of two or more of six mutations from five positions in protease
R D MacArthur and others.
•[P183] Injection site reactions (ISR) and success of HAART influence continued use of enfuvirtide (T20)
M Vogel and others.
•[P30] A pilot 48 week study of once daily (180mg QD) vs twice daily (90mg BID) enfuvirtide (ENF)
D Wright and others.
•[P47] Enfuvirtide + NRTIs for the treatment of HIV infected patients with concurrent active mycobacterial infection: a pilot experience
C Allavena and others.
•[P40] Inter-country variation in physician perspectives of enfuvirtide (ENF) prescribing
R Horne and others.
•[P56] Switching a toxicity-causing antiretroviral (ARV) to enfuvirtide (ENF) in patients with treatment-limiting toxicities
M Stoll and others.
•[P141] Mitochondrial DNA (mtDNA) content in enfuvirtide-treated healthy volunteers
G Garrabou and others.
•[P246] Friends of Fuzeon
K F MacRae and others.
•[P31] Durability of HIV RNA endpoints in treatment experienced patients analysis of POWER, RESIST and TORO trials
A Hill and others.
•[P24] Week 48 efficacy of TPV/r treatment is enhanced in patients with higher numbers of genotypically available background drugs in RESIST 1 and 2
A Lazzarin and others.
•[P23] Combined analysis of RESIST 96 week data: durability and efficacy of tipranavir/r in treatment experienced patients
B Gazzard and others.
 

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva
Norvir
Prezista
Reyataz
Viracept

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor
Sustiva
Viramune

Entry Inhibitors
 Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada